ozagrel and Liver-Neoplasms

ozagrel has been researched along with Liver-Neoplasms* in 2 studies

Trials

1 trial(s) available for ozagrel and Liver-Neoplasms

Article	Year
A thromboxane A2 synthetase inhibitor, OKY-046, reduces liver damage in hepatectomy. Surgery, 1993, Volume: 114, Issue:5 Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Diseases; Liver Neoplasms; Methacrylates; Thromboxane-A Synthase	1993

Other Studies

1 other study(ies) available for ozagrel and Liver-Neoplasms

Article	Year
[An experimental study evaluating the efficacy of platelet aggregation inhibitory (OKY-046) for hepatic metastasis of VX2 carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11 To investigate whether a platelet aggregation inhibitor (OKY-046) can inhibit VX2 tumor metastasis, VX2 tumor cells (1 x 10(7) cells) were inoculated into the portal vein and OKY-046 (an inhibitor of thromboxane A2 synthesis) was administered continuously at 0.2 mg/kg/hour (group A), and 0.6 mg/kg/hour (group B) into the portal vein from 30 min, before tumor cell inoculation through the following 2 days. In group C, adriamycin (ADM) 1 mg/kg was administered via the portal vein on the next day, 3rd, and 5th day after OKY-046 infusion was completed. Only ADM was administered into the portal vein on the 3rd, 5th and 7th day in group D and immediately and on the 2nd and 4th day after tumor cell inoculation in group E. The numbers of tumor nodules on the whole liver surface at three weeks after tumor inoculation in the control, group A, B, C, D and E were 546 +/- 79, 504.5 +/- 74, 438.8 +/- 59.9, 8 +/- 6.1, 130 +/- 89.7, and 9.5 +/- 5.3, respectively. These results suggest that the inhibitory effect of the tumor growth of OKY-046 depended on inhibition of extravasation of the portally inoculated VX2 tumor cells. Topics: Animals; Liver Neoplasms; Methacrylates; Rabbits; Thromboxane A2; Tumor Cells, Cultured	1993

Article

Year

[An experimental study evaluating the efficacy of platelet aggregation inhibitory (OKY-046) for hepatic metastasis of VX2 carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

To investigate whether a platelet aggregation inhibitor (OKY-046) can inhibit VX2 tumor metastasis, VX2 tumor cells (1 x 10(7) cells) were inoculated into the portal vein and OKY-046 (an inhibitor of thromboxane A2 synthesis) was administered continuously at 0.2 mg/kg/hour (group A), and 0.6 mg/kg/hour (group B) into the portal vein from 30 min, before tumor cell inoculation through the following 2 days. In group C, adriamycin (ADM) 1 mg/kg was administered via the portal vein on the next day, 3rd, and 5th day after OKY-046 infusion was completed. Only ADM was administered into the portal vein on the 3rd, 5th and 7th day in group D and immediately and on the 2nd and 4th day after tumor cell inoculation in group E. The numbers of tumor nodules on the whole liver surface at three weeks after tumor inoculation in the control, group A, B, C, D and E were 546 +/- 79, 504.5 +/- 74, 438.8 +/- 59.9, 8 +/- 6.1, 130 +/- 89.7, and 9.5 +/- 5.3, respectively. These results suggest that the inhibitory effect of the tumor growth of OKY-046 depended on inhibition of extravasation of the portally inoculated VX2 tumor cells.

Topics: Animals; Liver Neoplasms; Methacrylates; Rabbits; Thromboxane A2; Tumor Cells, Cultured

1993